Hepion Pharmaceuticals, Inc. (336.F)

0,0000 -9,2000 (-100,00%) Börsenschluss: 08:38AM CEST

Hepion Pharmaceuticals, Inc.

399 Thornall Street
First Floor
Edison, NJ 08837
United States
732 902 4000
https://www.hepionpharma.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 22

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. John T. Cavan	Interim CEO & CFO	462,18k	N/A	1958
Sharen Pyatetskaya	Director of Investor Relations	N/A	N/A	N/A
Dr. John Z. Sullivan-Bolyai	Part-Time Consultant	N/A	N/A	1948
Dr. Stephen A. Harrison FACP, M.D.	Scientific Advisory Board Chair & Consultant Medical Director	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in .

Beschreibung

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Corporate Governance

Hepion Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.